These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23984957)

  • 1. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).
    Esposito S; Prymula R; Zuccotti GV; Xie F; Barone M; Dull PM; Toneatto D
    Hum Vaccin Immunother; 2014; 10(7):2005-14. PubMed ID: 25424810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
    Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
    Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
    Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
    Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease.
    Watson PS; Novy PL; Friedland LR
    Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
    Gossger N; Snape MD; Yu LM; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Becker B; Kieninger D; Prymula R; Dull P; Ypma E; Toneatto D; Kimura A; Pollard AJ;
    JAMA; 2012 Feb; 307(6):573-82. PubMed ID: 22318278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.
    Richmond PC; Marshall HS; Nissen MD; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Beeslaar J; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Perez JL;
    Lancet Infect Dis; 2012 Aug; 12(8):597-607. PubMed ID: 22569484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.
    Sandbu S; Feiring B; Oster P; Helland OS; Bakke HS; Naess LM; Aase A; Aaberge IS; Kristoffersen AC; Rydland KM; Tilman S; Nøkleby H; Rosenqvist E
    Clin Vaccine Immunol; 2007 Sep; 14(9):1062-9. PubMed ID: 17634513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.
    Brendish NJ; Read RC
    Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?
    Findlow J
    Hum Vaccin Immunother; 2016; 12(1):235-8. PubMed ID: 26619037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
    Snape MD; Saroey P; John TM; Robinson H; Kelly S; Gossger N; Yu LM; Wang H; Toneatto D; Dull PM; Pollard AJ
    CMAJ; 2013 Oct; 185(15):E715-24. PubMed ID: 24062178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.